FINAL RESULTS OF PHASE II RANDOMIZED TRIAL OF AZACITIDINE VERSUS SUPPORT TREATMENT IN PATIENTS WITH LOW RISK MYELODYSPLASTIC SYNDROME WITHOUT THE 5Q DELETION

被引：1
|
作者：
Sanchez-Garcia, J. [1 ]
Falantes, J. [2 ]
Medina, A. [3 ]
Hernandez-Mohedo, F. [4 ]
Torres-Sabariego, A. [5 ]
Bailen, A. [6 ]
Sole, M.
Casano, J. [1 ]
Calderon, C.
Hermosin, L. [7 ]
Vahi, M. [5 ]
Serrano, J. [1 ]
机构：
[1] Univ Cordoba, Hematol, Reina Sofia Hosp, IMIBIC, Cordoba, Spain
[2] Univ Hosp Virgen Rocio, Hematol, Seville, Spain
[3] Hosp Costa Sol, Hematol, Marbella, Spain
[4] Hosp Costa Sol, Hematol, Granada, Spain
[5] Hosp Virgen Valme, Hematol, Seville, Spain
[6] Hosp Univ Carlos Haya, Hematol, Malaga, Spain
[7] Hosp Jerez, Hematol, Jerez de la Frontera, Spain
来源：
LEUKEMIA RESEARCH | 2015年 / 39卷
关键词：
D O I：
10.1016/S0145-2126(15)30115-6
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
114
引用
收藏
页码：S59 / S59
页数：1
相关论文
共 50 条
  • [21] EFFICACY AND SAFETY OF THE USE OF LENALIDOMIDE IN PATIENTS SUFFERING FROM MYELODYSPLASTIC SYNDROME WITHOUT DELETION OF 5Q DATA OF THE SPANISH REGISTRY OF SMD
    Sanchez Garcia, J.
    Diez Campelo, M.
    Ramos, F.
    Andreu, R.
    Santiago, O.
    Josefina, S.
    Javier, C.
    Sanz, G.
    HAEMATOLOGICA, 2015, 100 : 22 - 22
  • [22] Five-day versus 7-day treatment regimen with azacitidine in lower risk myelodysplastic syndrome: A phase 2, multicenter, randomized trial
    Park, Silvia
    Park, So Yeon
    Lee, Je-Hwan
    Choi, Eun-Ji
    Lee, Kyoo-Hyung
    Yoon, Sung-Soo
    Hong, Junshik
    Shin, Dong-Yeop
    Kim, Yoo-Jin
    CANCER, 2022, 128 (23) : 4095 - 4108
  • [23] Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the Groupe Francophone Des Myelodysplasies
    Ades, Lionel
    Prebet, Thomas
    Stamatoullas, Aspasia
    Recher, Christian
    Guieze, Romain
    Raffoux, Emmanuel
    Bouabdallah, Krimo
    Hunault, Mathilde
    Wattel, Eric
    Stalnikiewicz, Laure
    Toma, Andrea
    Dombret, Herve
    Vey, Norbert
    Sebert, Marie
    Gardin, Claude
    Chaffaut, Cendrine
    Chevret, Sylvie
    Fenaux, Pierre
    HAEMATOLOGICA, 2017, 102 (04) : 728 - 735
  • [24] Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents
    Park, Sophie
    Hamel, Jean-Francois
    Toma, Andrea
    Kelaidi, Charikleia
    Thepot, Sylvain
    Campelo, Maria Diez
    Santini, Valeria
    Sekeres, Mikkael A.
    Balleari, Enrico
    Kaivers, Jennifer
    Sapena, Rosa
    Goetze, Katharina
    Mueller-Thomas, Catharina
    Beyne-Rauzy, Odile
    Stamatoullas, Aspasia
    Kotsianidis, Ioannis
    Komrokji, Rami
    Steensma, David P.
    Fensterl, Jaime
    Roboz, Gail J.
    Bernal, Teresa
    Ramos, Fernando
    Calabuig, Marisa
    Guerci-Bresler, Agnes
    Bordessoule, Dominique
    Cony-Makhoul, Pascale
    Cheze, Stephane
    Wattel, Eric
    Rose, Christian
    Vey, Norbert
    Gioia, Daniela
    Ferrero, Dario
    Gaidano, Gianluca
    Cametti, Giovanni
    Pane, Fabrizio
    Sanna, Alessandro
    Germing, Ulrich
    Sanz, Guillermo F.
    Dreyfus, Francois
    Fenaux, Pierre
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (14) : 1591 - +
  • [25] G-CSF plus azacitidine versus azacitidine alone for patients with high-risk myelodysplastic syndrome: academic, open label, randomized trial
    Tomáš Stopka
    Lubomír Minařík
    Nina Dusilková
    Michal Pešta
    Vojtěch Kulvait
    Martin Špaček
    Zuzana Zemanová
    Marta Kalousová
    Anna Jonášová
    Blood Cancer Journal, 12
  • [26] G-CSF plus azacitidine versus azacitidine alone for patients with high-risk myelodysplastic syndrome: academic, open label, randomized trial
    Stopka, Tomas
    Minarik, Lubomir
    Dusilkova, Nina
    Pesta, Michal
    Kulvait, Vojtech
    Spacek, Martin
    Zemanova, Zuzana
    Kalousova, Marta
    Jonasova, Anna
    BLOOD CANCER JOURNAL, 2022, 12 (07)
  • [27] Preliminary Results from a Phase II Study of the Combination of Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome
    Chien, Kelly S.
    Cortes, Jorge E.
    Borthakur, Gautam
    DiNardo, Courtney D.
    Daver, Naval G.
    Jain, Nitin
    Naqvi, Kiran
    Jabbour, Elias J.
    Sheppard, Kimberly B.
    Pierce, Sherry A.
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    BLOOD, 2018, 132
  • [28] Lenalidomide Treatment for Lower Risk Nondeletion 5q Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Before Azacitidine
    Zeidan, Amer M.
    Al Ali, Najla H.
    Padron, Eric
    Lancet, Jeffrey
    List, Alan
    Komrokji, Rami S.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 (11): : 705 - 710
  • [29] Final Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome after Failure of Hypomethylating Agent Therapy
    Chien, Kelly S.
    Borthakur, Gautam
    Naqvi, Kiran
    Daver, Naval
    Bravo, Guillermo Montalban
    Cortes, Jorge E.
    DiNardo, Courtney D.
    Jabbour, Elias
    Alvarado, Yesid
    Andreeff, Michael
    Bose, Prithviraj
    Jain, Nitin
    Sheppard, Kimberly
    Klingner-Winton, Cheri
    Pierce, Sherry A.
    Dong, Xiao Qin
    Soltysiak, Kelly A.
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    BLOOD, 2020, 136
  • [30] Initial Results of a Randomized Phase II Study of Low Dose Decitabine (DAC) Versus Low Dose Azacitidine (AZA) in Patients with Low- or Intermediate-1-Risk Myelodysplastic Syndromes (MDS)
    Jabbour, Elias
    Sasaki, Koji
    Daver, Naval
    Pemmaraju, Naveen
    DiNardo, Courtney D.
    Kadia, Tapan
    Miller, Darla
    Sukholutsky, Victoria
    Huang, Xuelin
    Borthakur, Gautam
    Estrov, Zeev
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    BLOOD, 2014, 124 (21)
12345